Articles tagged with Vaccine Development
Researchers at Columbia University Irving Medical Center have developed a groundbreaking mouse model of typhoid fever, enabling the study and creation of more effective vaccines. The mouse model uses toll-like receptors to combat the infection, with promising results in immunizing mice against Salmonella typhi.
A team of Cardiff University scientists is working on a NATO project to develop an effective anthrax vaccine against the threat of bioterrorism. The goal is to protect civilians and workers at risk from infection with Bacillus anthracis.
Sanofi Pasteur's CYD-TDV vaccine candidate has shown promise in a phase IIb clinical trial, with effectiveness against DENV 1, 3 and 4 but not DENV 2. The results mark a significant step forward in dengue vaccine development.
A new dengue vaccine candidate, CYD-TDV, has shown promising results in a phase 2b trial with an effective rate of 60-90% against DENV 1, 3, and 4 viruses. The vaccine was also found to be safe and well-tolerated, with no serious adverse events reported.
A recent Special Focus in Human Vaccines & Immunotherapeutics discusses the mistakes of past cancer vaccine programs and provides critical insights into the future of cancer vaccines. The study emphasizes the importance of antigen discovery and personalized approaches to overcome the challenges of tumor heterogeneity.
Lawrence Corey, a renowned expert in virology and immunology, has been honored with the Cubist-ICAAC Award for his pioneering work on herpes viruses, HIV, and cancer. His research has led to significant advances in antiviral therapy and vaccine development.
Dartmouth medical research has made a breakthrough in developing a new tuberculosis vaccine, DAR-901. The vaccine, produced by growing bacteria related to TB on agar plates and then inactivating them with heat, has shown a statistically significant reduction of 39% in the rate of tuberculosis among HIV-infected patients.
Researchers successfully developed a highly effective vaccine against the deadly Nipah virus, which has shown complete protection in African green monkeys with no evidence of disease. The vaccine, known as Hendra-sG, is a recombinant piece of the virus produced in the laboratory and can be used safely for human treatment.
Researchers have developed a vaccine that protects African green monkeys from Nipah virus, with all nine vaccinated animals surviving a lethal challenge. The vaccine is based on a Hendra virus surface protein and is in commercial development for use in horses.
Researchers at Arizona State University develop first vaccine complex that can be delivered safely and effectively by piggybacking onto self-assembled, three-dimensional DNA nanostructures. The vaccine complexes trigger a robust immune response up to 9-fold higher than traditional methods.
The new FMD vaccine is a molecular vaccine that does not use live FMD virus, allowing for differentiation between vaccinated and infected animals. This breakthrough could significantly reduce the economic impact of FMD outbreaks in the US, with potential cost savings estimated to exceed $50 billion.
A new study published in Vaccine indicates that the cost of producing a tetravalent dengue vaccine could be as low as $0.20 per dose with an annual production level of 60 million doses. This finding provides confidence to ministries of health to plan for the inclusion of dengue vaccine in their immunization programs.
Researchers have identified a master regulator gene, Spi-B, essential for the development of M cells, which play a crucial role in initiating immune responses. This discovery could aid research on oral vaccines and inflammatory bowel diseases by providing valuable insights into M cell differentiation and function.
Levine pioneered molecular approaches to develop live oral vaccines, including attenuated Salmonella Typhi and Shigella. He has made significant contributions to vaccine research, including epidemiologic field studies and large-scale controlled trials.
Researchers developed a technique to genetically differentiate Plasmodium falciparum parasites, linking infection with new parasites to the risk of clinical disease. This tool could help evaluate new prevention strategies and vaccines, as well as understand how anti-malarial treatments work.
Researchers at Oregon Health & Science University's ONPRC have discovered a new method for creating vaccines that is thought to be safer and more effective than current approaches. The approach uses hydrogen peroxide to inactivate viruses for use as vaccines, showing protective vaccine-induced immunity against three diseases: West Nile...
Researchers created an innovative biomimetic model of the human immune system called MIMIC®, enabling faster and more effective vaccine development. The MIMIC platform provides a novel in vitro model for evaluating human immune responses against candidate drugs, adjuvants, and vaccines.
The Georgia Institute of Technology will develop an energy-optimized warehousing and distribution system for vaccines and drugs in developing countries. The project aims to minimize environmental impact, energy consumption, and storage costs by employing low-energy cooling techniques.
The introduction of rotavirus vaccines in developing countries is projected to save more than 2.4 million lives by 2030, with significant reductions in hospitalizations and clinical visits. Rotavirus vaccines are highly cost-effective, reducing child deaths by up to 95% in GAVI-eligible countries.
Lorne Babiuk, a renowned vaccine researcher, has been awarded the prestigious Canada Gairdner Wightman Award for his outstanding leadership in vaccine development and research. He is recognized for his work on developing six world-first livestock vaccines and creating a vaccine against rotavirus in calves that led to a human vaccine.
Scientists have made significant progress in building knowledge and infrastructure to develop novel tuberculosis vaccine candidates. The next decade of research will focus on investigating remaining fundamental questions and leveraging recent innovations in systems biology, genomics, and bioinformatics.
Researchers and experts call for intensified global collaboration to develop effective new vaccines against tuberculosis. The blueprint outlines a path forward to create more effective, safe vaccines that can protect people from childhood TB, pulmonary TB, and latent TB.
The Bill & Melinda Gates Foundation grants Aeras up to $220 million to develop safe and effective TB vaccines amid rising drug-resistant strains. The funding aims to accelerate global efforts to eliminate the airborne threat.
The Infectious Disease Research Institute (IDRI) has received a $1 million grant from RHSC to develop an effective diagnostic tool and vaccine for leprosy. Current approaches are insufficient to eliminate the disease as a public health problem, with 1.6 billion people at risk of exposure.
Researchers at SFU have discovered a benign bacterium, Rhizobium radiobacter, with sugar molecules resembling those on the surface of HIV. This resemblance could trigger an immediate immune response against the virus, potentially leading to the development of a preventative vaccine.
The International Vaccine Institute (IVI) has been granted two US patents on novel Shigella protein antigens and methods, paving the way for an effective and low-cost vaccine against bacillary dysentery. The vaccine has the potential to provide cross-protection across species and serotypes of Shigella.
The first clinical trial of a new vaccine for visceral leishmaniasis has begun, targeting the most deadly form of the disease. The Phase 1 trial will evaluate the safety and immunogenicity of the vaccine in 36 adult volunteers in Washington State and India.
A University of Alberta researcher has developed a vaccine that shows signs of prevention against all strains of hepatitis C. The vaccine was tested on humans and elicited broad cross-neutralizing antibodies against major strains, offering hope for those with the disease.
Youssef Kousa, a fifth-year osteopathic student, has been awarded the prestigious Ruth L. Kirschstein National Research Service Award for his work on identifying causes of cleft palate. He will use this fellowship to study gene mutations and develop interventions to prevent birth defects.
A new MSU project aims to collect local data on preventable bacterial infections and spurs vaccine use and development in Nigeria and neighboring countries. The research focuses on diseases like pneumonia, sepsis, and meningitis, with the goal of increasing vaccine uptake and monitoring their impact.
The SAV001 vaccine, developed by Dr. Chil-Yong Kang's team, has shown strong immune responses in preliminary tests with no adverse effects. It is the only HIV vaccine under development in Canada and one of few globally.
A new TB vaccine candidate has entered Phase I clinical trials in South Africa to assess its safety and immunogenicity in latently infected adults. The vaccine, SSI H56-IC31, has shown efficacy in pre-clinical studies and holds promise for preventing active TB disease in a vast population.
Researchers have identified an antibody that neutralizes Sudan virus, one of the most deadly human pathogens caused by ebolavirus. The new findings suggest a key spot for neutralizing ebolaviruses, which could lead to the development of effective vaccines and antibody-based therapies.
Shanchol, a new oral cholera vaccine developed by IVI, has been prequalified by the World Health Organization for use in developing countries. The vaccine is ready to be used in large-scale immunization programs and has been shown to be safe and protective against cholera for three years.
A new study from Johns Hopkins Bloomberg School of Public Health developed a method to better estimate vaccine coverage, combining administrative data with survey data. The results show that estimates of routine immunization activities are substantially lower than previously thought in some countries, such as Madagascar and Sierra Leone.
The Phase III trial of RTS,S, a malaria vaccine candidate, demonstrates significant protection against clinical and severe malaria in African children aged 5 to 17 months. The results show the vaccine can provide young African children with significant protection against malaria, with an acceptable safety and tolerability profile.
Researchers at the University of Southampton have made a significant breakthrough in understanding Chlamydia trachomatis genetics, enabling the development of new treatments and potentially a vaccine. This breakthrough could lead to improved treatment options for the disease, which is often left untreated due to its asymptomatic nature.
A live-attenuated Chlamydia bacteria-based vaccine has been shown to protect monkeys from developing severe eye disease and blinding trachoma. The vaccine demonstrated robust immune responses and prevented infection in up to 50% of vaccinated monkeys.
Researchers at LLNL and Loyola University have received a $3.5 million NIH grant to develop a new anthrax vaccine using nanolipoprotein technology. The NLP-based vaccine has shown potential in preventing disease and protecting people, with flexible formulation and robustness.
Scientists are developing a vaccine against East Coast fever, a destructive disease in eastern and central Africa, with the potential to also protect US cattle. The collaboration aims to control tick-borne diseases, supporting international food security.
Two scientists, Dr. Thomas Kosten and Dr. Peter Burkhard, will receive funding to develop a vaccine against methamphetamine addiction and a peptide nanoparticle nicotine vaccine. The vaccines are expected to undergo initial clinical trials within the next five years.
Researchers have successfully assembled the Bluetongue virus outside a cell, paving the way for the development of more effective vaccines. This breakthrough could lead to vaccines with useful new properties, such as tags that distinguish vaccinated animals from those that have recovered.
A European joint project, HCVAX, is developing a novel hepatitis C vaccine based on nanotechnology. The vaccine uses biocompatible nanogels to bring genetic information of the virus into the body, triggering an immune response.
A new discovery has been made in the fight against plague and bacterial pneumonias by researchers at the Trudeau Institute. They have identified a single component of the plague causing bacterium that can be used as a vaccine, offering a potential safer alternative to existing vaccines.
Despite progress in vaccine distribution for childhood killer diseases, global efforts to combat neglected tropical diseases (NTDs) are lagging, argue researchers. NTDs, which affect the world's poorest, require more R&D funding and investment to develop effective vaccines.
A report by the International Vaccine Access Center highlights the poor availability of essential health products in Sub-Saharan Africa, particularly in remote areas. The report explores how public-private partnerships can improve distribution systems and enhance access to essential medicines.
New opportunities exist to overcome remaining vaccine challenges and save 6.4 million lives over the next decade, Health Affairs reports. The Bill & Melinda Gates Foundation has committed $10 billion to make life-saving vaccines available to millions of children.
The Lancet's new Series on vaccines highlights four key elements: intensified research, advocacy at the highest level, developing countries' responsibility, and expanded communication of benefits. Experts emphasize the need for $3.7 billion funding to save 4 million lives through immunization programs.
Developing vaccines against diseases with extensive antigenic variability, such as HIV and malaria, poses significant technical challenges. Tailored vaccination programmes based on individual genetic predispositions could increase safety and efficacy.
The new decade of vaccines brings hope for disease prevention through innovative technologies like glycoconjugate vaccines and reverse vaccinology. Despite challenges, vaccines have already led to significant reductions in morbidity and mortality due to diseases like smallpox, measles, and meningitis.
Vaccine development for 'big three' diseases is being accelerated by new approaches like systems biology and structure-based antigen design. Systems biology enables the capture of massive biological data to predict vaccine behavior.
A new experimental vaccine has shown promising results in protecting horses against the deadly Hendra virus, according to CSIRO scientists. The vaccine's successful development could help prevent the spread of the disease from flying foxes to horses and ultimately to people.
Control of infectious diseases such as cholera, diarrhoea, Chagas disease, and those preventable by vaccination have been successful in Brazil. However, failures exist, including the ongoing public health problem of dengue fever and visceral leishmaniasis.
A mathematical approach has been developed to make complex combination vaccines more affordable for developing countries. The model considers key factors in providing accessible vaccines, including production capacity and pricing strategies.
A Wayne State University School of Medicine researcher has developed a potential vaccine for Chlamydia, targeting the disease's leading causes of blindness and infertility. The technology demonstrates a successful vaccine effect in an animal model, paving the way for human trials and potentially significant public health benefits.
A new vaccine has been developed by McMaster University researchers, effective in treating people with cat allergies. The peptide immunotherapy vaccine is given through skin injections and may require fewer doses than traditional allergy shots, reducing side effects.
Researchers have developed an experimental vaccine against the human norovirus, generating a strong immune response in mice. The vaccine uses a novel viral vector-based method and showed promise in inducing high levels of antibodies and a robust white blood cell response in animals.
Researchers at the University of Copenhagen have developed a new vaccine technology that stimulates and accelerates the immune system to show its defense mechanisms against hepatitis C virus. The technology works by presenting a larger section of the internal molecule, allowing the immune defenses to recognize and respond to it.
At least one dengue vaccine could be licensed within the next 4 years. Developing countries' national regulatory authorities (NRAs) have a crucial role in accelerating the licensure process when a new dengue vaccine becomes available.
Recent meetings discussed regulatory challenges for dengue vaccines, including issues with funding, ethics and trials. A registry has been established to track systematic reviews, promoting transparency in healthcare decision-making.